Bragar Eagel & Squire, P.C. said a securities class action has been filed against Replimune Group Inc. in the U.S. District Court for the District of Massachusetts on behalf of investors who purchased or acquired Replimune securities between Oct. 20, 2025, and April 10, 2026. Investors seeking appointment as lead plaintiff must apply by Oct. 5, 2026. The complaint alleges Replimune did not resolve FDA-communicated concerns over study design in connection with its Biologics License Application, or BLA. It also alleges the company submitted data from an early, unplanned RP1-104 analysis involving 40 patients, or 10% of the planned 400-patient enrollment, and that deficiencies in RPL-001-16 and RP1-104 were likely to result in FDA rejection of the BLA. Replimune trades on Nasdaq under the ticker REPL.